EGFR and non-small cell lung carcinoma: Although ICIs have revolutionized the systemic treatment of patients of NSCLC with EGFRwild-type (WT), the activity and clinical impact in the subgroup of EGFR mutation-positive tumors have been lower than in the EGFRWT population in large 2nd- and 3rd-line phase III trials and 1st-line trials evaluating the efficacy of ICIs often excluded EGFR-mutation-positive patients.